Two plaintiffs' lawyers experienced in pharma liability litigation have been tapped to lead the group managing thousands of suits alleging that Takeda Pharmaceutical's diabetes drug Actos caused bladder cancer, Bloomberg reports.
AstraZeneca is seeking an injunction to block Seroquel copies at least until a court can review its claims. The drugmaker says the FDA shouldn't be allowed to usher generic Seroquel onto the market until Dec. 2, when data exclusivity expires.
Litigation is testing whether manufacturing problems at a pharmaceutical plant that led to a drug shortage can be considered legal negligence--as well as whether the manufacturer can be held accountable for patients' deaths.
Tekmira Pharmaceuticals ($TKMR) fired back at Alnylam Pharmaceuticals ($ALNY) in federal court this week, with an attempt to get rid of the Massachusetts company's patent lawsuit over siRNA and lipid nanoparticle drug delivery technology.
Another batch of sales reps has sued Novo Nordisk ($NVO) for overtime. The would-be class action suit, which was filed by two reps, is seeking $70 million in overtime pay. Like so many other lawsuits--pending and otherwise--this one alleges a drugmaker misclassified its reps as exempt salaried workers when they should have been eligible for overtime.
Teva Pharamaceuticals ($TEVA) is discovering size matters. The Israeli generics giant reportedly is setting aside $285 million to settle lawsuits alleging the jumbo-sized vials it used for its...
A New Jersey jury has let Johnson & Johnson's ($JNJ) Risperdal off the hook for a patient's diabetes. But the panel determined that the company didn't do enough to warn the man's...
GlaxoSmithKline ($GSK) has reached a deal to settle another 20,000 lawsuits over its diabetes drug Avandia, a lawyer for the plaintiffs told Bloomberg. The settlement came out of court-ordered
Pfizer ($PFE) employees at the company's manufacturing hub in Puerto Rico are not happy with what company shenanigans did to Pfizer's stock price and to their retirement plans. They allege in...
Rack up another win for pharma sales reps seeking overtime pay. Novartis ($NVS) has agreed to pay $99 million to settle a class-action lawsuit that's been slogging its way through the courts since